Olema Pharmaceuticals Inc (OLMA)

$11.88

+0.25

(+2.15%)

Market is closed - opens 7 PM, 25 Jun 2024

Insights on Olema Pharmaceuticals Inc

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 78.5% return, outperforming this stock by 30.7%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 245.4% return, outperforming this stock by 304.0%

Performance

  • $11.67
    $12.00
    $11.88
    downward going graph

    1.77%

    Downside

    Day's Volatility :2.75%

    Upside

    1.0%

    downward going graph
  • $7.68
    $17.79
    $11.88
    downward going graph

    35.35%

    Downside

    52 Weeks Volatility :56.83%

    Upside

    33.22%

    downward going graph

Returns

PeriodOlema Pharmaceuticals IncSector (Health Care)Index (Russel 2000)
3 Months
6.02%
0.9%
0.0%
6 Months
-20.34%
8.7%
0.0%
1 Year
43.05%
11.2%
0.0%
3 Years
-58.57%
17.3%
-24.2%

Highlights

Market Capitalization
650.0M
Book Value
$4.23
Earnings Per Share (EPS)
-2.0
Wall Street Target Price
27.29
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-30.61%
Return On Equity TTM
-48.31%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
EBITDA
-112.1M
Diluted Eps TTM
-2.0
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-2.36
EPS Estimate Next Year
-2.57
EPS Estimate Current Quarter
-0.55
EPS Estimate Next Quarter
-0.58

Analyst Recommendation

Buy
    93%Buy
    6%Hold
    0
    0%Sell
Based on 16 Wall street analysts offering stock ratings for Olema Pharmaceuticals Inc(by analysts ranked 0 to 5 stars)
Based on 16 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
15
14
14
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 129.71%

Current $11.88
Target $27.29

Technicals Summary

Sell

Neutral

Buy

Olema Pharmaceuticals Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Olema Pharmaceuticals Inc
Olema Pharmaceuticals Inc
28.37%
-20.34%
43.05%
-58.57%
-76.27%
Moderna, Inc.
Moderna, Inc.
-19.93%
37.06%
10.79%
-39.4%
850.14%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
6.92%
23.97%
34.26%
93.43%
236.95%
Novo Nordisk A/s
Novo Nordisk A/s
4.35%
38.25%
80.59%
245.4%
453.56%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
2.57%
14.98%
34.9%
144.2%
158.93%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Olema Pharmaceuticals Inc
Olema Pharmaceuticals Inc
NA
NA
NA
-2.36
-0.48
-0.31
NA
4.23
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-6.7
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
30.93
30.93
1.46
44.13
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
49.78
49.78
2.36
3.47
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
30.61
30.61
0.53
17.09
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Olema Pharmaceuticals Inc
Olema Pharmaceuticals Inc
Buy
$650.0M
-76.27%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$51.5B
850.14%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$115.3B
236.95%
30.93
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$644.0B
453.56%
49.78
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$121.7B
158.93%
30.61
39.46%

Institutional Holdings

  • Bvf Inc

    16.33%
  • Paradigm Biocapital Advisors LP

    14.13%
  • Logos Global Management LP

    7.84%
  • Deep Track Capital, LP

    5.77%
  • BlackRock Inc

    5.75%
  • State Street Corporation

    5.68%

Company Information

olema oncology is a biopharmaceutical company developing innovative targeted therapies for women’s cancers. our lead program, op-1250, a potential best-in-class complete estrogen receptor antagonist (ceran), is in development to treat estrogen receptor-positive (er+), human epidermal growth factor receptor 2-negative (her2-) breast cancer. olema recently initiated a phase 1/2 dose-escalation and expansion clinical trial of op-1250. we are supported in our mission by experienced and accomplished scientists and board members, leading healthcare investors and some of the most innovative pharma companies. for more information about the company please visit www.olema.com.

Organization
Olema Pharmaceuticals Inc
Employees
75
CEO
Dr. Sean P. Bohen M.D., Ph.D.
Industry
Health Technology

FAQs